Phase Genomics
Phase Genomics provides ultra-long-range genome sequencing technology and computational tools for researchers in genomics, cytogenetics, oncology, and microbiology. Its products enable genomic profiling, metagenome deconvolution, viral genome reconstruction, and detection of chromosomal abnormalities in a variety of organisms. The organization aims to empower scientists with advanced genomic tools to accelerate discoveries in health, agriculture, and environmental research.
Facts
- HQ
- Seattle, WA 98109
- Sectors
- Biotechnology Research
- Founded
- 2015
- Type
- Corporation Seattle business license
- Employees
- 15
- Registered name
- Phase Genomics Inc Seattle business license
- Stage
- startup
- Members see funding amounts. .
- Founders
- Ivan Liachko, Jay Shendure, PhD, Maitreya Dunham, PhD
Is this your organization? Claim it
A DNA Typewriter reconstructs mouse cell lineage from zygote to late organogenesis (Qi Yu, Jay Shendure et al.; DOI 10.1126/science.ael0508)
The paper demonstrates a DNA Typewriter system that records cell lineage information across mouse development, reconstructing lineage history from the zygote through late organogenesis. The study reports authorship led by Qi Yu and Jay Shendure with extensive contributor lists and DOI 10.1126/science.ael0508.
Life Science Washington Institute’s WIN Mentoring Program Helps SafKan Health Secure FDA 510(k), Clinic Adoption, and $13M+ Funding to Scale OtoSet
Life Science Washington Institute’s Washington Innovation Network (WIN) Mentoring Program has spent a decade helping early-stage life-science companies — including Redmond-based SafKan Health — navigate regulation and fundraising, contributing to SafKan’s FDA 510(k) clearance, clinic adoption, and multiple funding rounds. SafKan’s OtoSet ear-cleaning system is FDA-cleared for clinical use, has entered hundreds of U.S. clinics, and the company aims for home-use approval and a Series B round next year.
Phase Genomics Secures $2.5M to Develop AI Platform for Detecting Cancer Chromosomal Aberrations
Seattle startup Phase Genomics received $2.5 million in funding, including $2 million from the U.S. National Cancer Institute and $500,000 from Washington state's Andy Hill CARE Fund, to advance its AI-driven platform that detects chromosomal aberrations in cancer. The funding supports projects analyzing tumor samples to develop predictive scores for cancers like acute myeloid leukemia and colorectal cancer.
See all 15 news stories about Phase Genomics.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
People
-
Ivan Liachko Founder & CEO
-
Kayla Young Executive, Executive Officer, COO